IP Library Granted Patent US 8,221,410
Granted Patent B2
US 8,221,410 · App. 12/323,700 · Granted Jul 17, 2012

Methods for creating tissue effect utilizing electromagnetic energy and a reverse thermal gradient

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,221,410
App. No.
12/323,700
Granted
Jul 17, 2012
Kind
B2
Abstract

A method of creating a tissue effect at a tissue site delivers electromagnetic energy through a skin surface from an electromagnetic energy delivery device coupled to an electromagnetic energy source. At least one of the electromagnetic energy delivery device or electromagnetic energy source includes a memory. A reverse thermal gradient is created through the skin surface to sufficiently heat an underlying tissue site to provide that a temperature of the skin surface is lower than a temperature of the underlying tissue. Information is stored from the memory to facilitate operation of at least one of the electromagnetic energy delivery device or the electromagnetic energy source. Electromagnetic energy is applied through the skin surface to the underlying tissue. A tissue effect is created on at least a portion of the tissue site.

Claims (35)

1. A method of creating a tissue effect at a tissue site using an electromagnetic energy delivery device, the method comprising:

delivering electromagnetic energy from the electromagnetic energy delivery device transcutaneously through a skin surface;

creating a reverse thermal gradient through the skin surface to sufficiently heat an underlying tissue, wherein a temperature of the skin surface is lower than a temperature of the underlying tissue;

detecting the temperature of the skin surface;

heating the skin surface and underlying tissue in response to the detected temperature of the skin surface; and

using the electromagnetic energy to create the tissue effect in at least a portion of the tissue site.

2. The method of claim 1 , wherein the tissue effect is dermal remodeling, dermal tightening, wrinkle reduction, elastosis reduction, scar reduction, sebaceous gland removal or deactivation, reduction of sebaceous gland activity, hair follicle modification, adipose tissue remodeling or removal, spider vein removal, modification of skin irregularities, creation of scar or nascent collagen, or modification of skin pore size.

3. The method of claim 1 , wherein the tissue effect is a reduction of skin bacteria activity or unclogging of skin pores.

4. The method of claim 1 , further comprising:

storing information in a memory coupled to facilitate operation of at least one of the electromagnetic energy delivery device or an electromagnetic energy source coupled with the electromagnetic energy delivery device.

5. A method for creating a tissue effect at a tissue site using an RF energy delivery device with an energy delivery surface, the method comprising:

coupling the RF energy delivery surface with a skin surface;

creating a reverse thermal gradient through the skin surface to sufficiently heat the tissue, wherein a temperature of the skin surface is lower than a temperature of the underlying tissue;

detecting the temperature of the skin surface;

delivering RF energy from the RF energy delivery device transcutaneously through the skin surface to the underlying tissue in response to the detected temperature of the skin surface; and

using the RF energy to create the tissue effect on at least a portion of the tissue site.

6. The method of claim 5 , wherein the tissue effect is dermal remodeling, dermal tightening, wrinkle reduction, elastosis reduction, scar reduction, sebaceous gland removal or deactivation, reduction of sebaceous gland activity, hair follicle modification, adipose tissue remodeling or removal, spider vein removal, modification of skin irregularities, creation of scar or nascent collagen, or modification of skin pore size.

7. The method of claim 5 , wherein the tissue effect is a reduction of skin bacteria activity or unclogging of skin pores.

8. The method of claim 5 , further comprising:

storing information in a memory coupled to facilitate operation of at least one of the RF energy delivery device or an RF energy source coupled with the RF energy delivery device.

9. A method of creating a tissue effect using an energy delivery device, the method comprising:

reducing a temperature of at least a portion of a skin surface, wherein the temperature of the skin surface is less than the temperature of an underlying tissue when the temperature of the skin surface is reduced;

non-continuously delivering electromagnetic energy in a transcutaneous manner from the electromagnetic energy delivery device through the skin surface to the underlying tissue; and

using the electromagnetic energy to create the tissue effect on at least a portion of the underlying tissue.

10. The method of claim 9 , wherein the tissue effect is dermal remodeling, dermal tightening, wrinkle reduction, elastosis reduction, scar reduction, sebaceous gland removal or deactivation, reduction of sebaceous gland activity, hair follicle modification, adipose tissue remodeling or removal, spider vein removal, modification of skin irregularities, creation of scar or nascent collagen, or modification of skin pore size.

11. The method of claim 9 , wherein the tissue effect is a reduction of skin bacteria activity or unclogging of skin pores.

12. The method of claim 9 , further comprising:

storing information in a memory coupled to facilitate operation of at least one of the electromagnetic energy delivery device or an electromagnetic energy source coupled with the electromagnetic energy delivery device.

13. A method of creating a tissue effect using an electromagnetic energy delivery device, the method comprising:

non-continuously reducing a temperature of at least a portion of a skin surface, wherein the temperature of the skin surface is less than the temperature of an underlying tissue; and

transcutaneously delivering electromagnetic energy from the electromagnetic energy delivery device to create the tissue effect in at least a portion of the underlying tissue.

14. The method of claim 13 , wherein the tissue effect is dermal remodeling, dermal tightening, wrinkle reduction, elastosis reduction, scar reduction, sebaceous gland removal or deactivation, reduction of sebaceous gland activity, hair follicle modification, adipose tissue remodeling or removal, spider vein removal, modification of skin irregularities, creation of scar or nascent collagen, or modification of skin pore size.

15. The method of claim 13 , wherein the tissue effect is a reduction of skin bacteria activity or unclogging of skin pores.

16. The method of claim 13 , further comprising:

storing information in a memory coupled to facilitate operation of at least one of the electromagnetic energy delivery device or an electromagnetic energy source coupled with the electromagnetic energy delivery device.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Jul 18, 2016
From: SOLTA MEDICAL, INC.
To: BARCLAYS BANK PLC
Reel/Frame 039178/0970 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 27, 2014
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: SOLTA MEDICAL, INC.
Reel/Frame 032126/0206 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 27, 2014
From: SILICON VALLEY BANK
To: SOLTA MEDICAL, INC.
Reel/Frame 032126/0475 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Nov 19, 2013
From: SOLTA MEDICAL, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031674/0546 →
SECURITY INTEREST - MEZZANINE LOAN Recorded Apr 24, 2013
From: SOLTA MEDICAL, INC.
To: SILICON VALLEY BANK
Reel/Frame 030281/0524 →
SECURITY AGREEMENT Recorded Jun 16, 2009
From: SOLTA MEDICAL, INC.
To: SILICON VALLEY BANK
Reel/Frame 022824/0837 →